Somewhat Positive Press Coverage Somewhat Unlikely to Impact Nabriva Therapeutics (NBRV) Share Price

News articles about Nabriva Therapeutics (NASDAQ:NBRV) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nabriva Therapeutics earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.4377546090308 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

NBRV has been the topic of a number of analyst reports. Zacks Investment Research raised Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a research report on Wednesday, October 11th. HC Wainwright boosted their price target on Nabriva Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 1st. Needham & Company LLC reissued a “buy” rating and issued a $18.00 price target (up from $15.00) on shares of Nabriva Therapeutics in a report on Tuesday, September 19th. Wedbush reissued an “outperform” rating and issued a $21.00 price target (up from $13.00) on shares of Nabriva Therapeutics in a report on Monday, September 18th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Nabriva Therapeutics in a research note on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Nabriva Therapeutics currently has an average rating of “Buy” and an average target price of $18.61.

Shares of Nabriva Therapeutics (NBRV) traded down $0.03 during trading on Monday, reaching $6.18. The company’s stock had a trading volume of 74,200 shares, compared to its average volume of 126,078. The company has a market cap of $226.75 and a P/E ratio of -0.24. Nabriva Therapeutics has a 12 month low of $4.75 and a 12 month high of $14.10.

Nabriva Therapeutics (NASDAQ:NBRV) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.07). Nabriva Therapeutics had a negative net margin of 985.30% and a negative return on equity of 80.69%. equities analysts forecast that Nabriva Therapeutics will post -2.58 EPS for the current fiscal year.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Nabriva Therapeutics (NBRV) Share Price” was posted by BBNS and is owned by of BBNS. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-nabriva-therapeutics-nbrv-share-price/1818457.html.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.